[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fNWt7JOvj1ap4cIrHU7srPbvkLirf_KzXCOiATSwtvcc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Instituto Valenciano de Infertilidad, IVI VALENCIA",[4],72,false,5,9,13675,2,50,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"Infertility",11,{"name":18,"count":19},"Infertility, Female",10,{"name":21,"count":22},"Reproductive Sterility",3,{"name":24,"count":22},"Ovarian Hyperstimulation Syndrome",{"name":26,"count":22},"Sperm Selection",{"name":28,"count":22},"Ovarian Stimulation",{"name":30,"count":11},"Healthy",{"name":32,"count":11},"Pregnancy",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06193135","Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)","2025-12-31","Corifolitropin Alfa",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,71,89,116,134,160,178,203,229,253,278,303,321,339,361,386,404,430,454,472,493,519,543,567,591,609,635,653,678,702,720,745,763],{"intervention":38,"totalTrials":48,"cells":49},1,{"EARLY_PHASE1":50,"PHASE1":53,"PHASE2":55,"PHASE3":57,"PHASE4":59,"NA":61},{"trials":51,"activeCount":52},[],0,{"trials":54,"activeCount":52},[],{"trials":56,"activeCount":52},[],{"trials":58,"activeCount":52},[],{"trials":60,"activeCount":52},[],{"trials":62,"activeCount":48,"soonestReadout":37},[63],{"nctId":35,"briefTitle":36,"status":64,"phases":65,"primaryCompletion":37,"completion":37,"start":66,"enrollment":67,"conditions":68,"interventions":69},"RECRUITING",[45],"2025-07-08",318,[18,21],[38,70],"Folitropin Beta",{"intervention":70,"totalTrials":48,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":83},{"trials":74,"activeCount":52},[],{"trials":76,"activeCount":52},[],{"trials":78,"activeCount":52},[],{"trials":80,"activeCount":52},[],{"trials":82,"activeCount":52},[],{"trials":84,"activeCount":48,"soonestReadout":37},[85],{"nctId":35,"briefTitle":36,"status":64,"phases":86,"primaryCompletion":37,"completion":37,"start":66,"enrollment":67,"conditions":87,"interventions":88},[45],[18,21],[38,70],{"intervention":90,"totalTrials":48,"cells":91},"Menopur®, Ferring",{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":100,"NA":114},{"trials":93,"activeCount":52},[],{"trials":95,"activeCount":52},[],{"trials":97,"activeCount":52},[],{"trials":99,"activeCount":52},[],{"trials":101,"activeCount":52},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT00820482","Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination.","COMPLETED",[44],"2009-05","2009-01",80,[111],"Ovarian Stimulation Preceding Intrauterine Insemination",[90,113],"rFSH (Gonal®,",{"trials":115,"activeCount":52},[],{"intervention":113,"totalTrials":48,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":132},{"trials":119,"activeCount":52},[],{"trials":121,"activeCount":52},[],{"trials":123,"activeCount":52},[],{"trials":125,"activeCount":52},[],{"trials":127,"activeCount":52},[128],{"nctId":103,"briefTitle":104,"status":105,"phases":129,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":130,"interventions":131},[44],[111],[90,113],{"trials":133,"activeCount":52},[],{"intervention":135,"totalTrials":48,"cells":136},"COS with GnRH antagonists and rFSH",{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":158},{"trials":138,"activeCount":52},[],{"trials":140,"activeCount":52},[],{"trials":142,"activeCount":52},[],{"trials":144,"activeCount":52},[],{"trials":146,"activeCount":52},[147],{"nctId":148,"briefTitle":149,"status":105,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},"NCT02738580","Follicular Steroid Genesis in Controlled Ovarian Stimulation",[44],"2018-06-15","2016-10-18",112,[15,155],"Controlled Ovarian Hyperstimulation",[135,157],"COS with GnRH antagonists and HP-HMG",{"trials":159,"activeCount":52},[],{"intervention":157,"totalTrials":48,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":176},{"trials":163,"activeCount":52},[],{"trials":165,"activeCount":52},[],{"trials":167,"activeCount":52},[],{"trials":169,"activeCount":52},[],{"trials":171,"activeCount":52},[172],{"nctId":148,"briefTitle":149,"status":105,"phases":173,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":174,"interventions":175},[44],[15,155],[135,157],{"trials":177,"activeCount":52},[],{"intervention":179,"totalTrials":48,"cells":180},"Progesterone",{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":201},{"trials":182,"activeCount":52},[],{"trials":184,"activeCount":52},[],{"trials":186,"activeCount":52},[],{"trials":188,"activeCount":52},[],{"trials":190,"activeCount":52},[191],{"nctId":192,"briefTitle":193,"status":105,"phases":194,"primaryCompletion":195,"completion":37,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT04499131","Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters",[44],"2025-04-30","2021-12-09",109,[18,199],"ENDOMETRIAL RECEPTIVITY",[179],{"trials":202,"activeCount":52},[],{"intervention":204,"totalTrials":48,"cells":205},"Bone Marrow CD133+ Stem Cell Transplantation",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":227},{"trials":207,"activeCount":52},[],{"trials":209,"activeCount":52},[],{"trials":211,"activeCount":52},[],{"trials":213,"activeCount":52},[],{"trials":215,"activeCount":52},[216],{"nctId":217,"briefTitle":218,"status":105,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":226},"NCT02144987","Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy",[44],"2014-09","2013-04",16,[224,225],"Asherman's Syndrome","Endometrium; Atrophy, Cervix",[204],{"trials":228,"activeCount":52},[],{"intervention":230,"totalTrials":48,"cells":231},"Tryptorelin",{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":251},{"trials":233,"activeCount":52},[],{"trials":235,"activeCount":52},[],{"trials":237,"activeCount":52},[],{"trials":239,"activeCount":52},[],{"trials":241,"activeCount":52},[242],{"nctId":243,"briefTitle":244,"status":105,"phases":245,"primaryCompletion":246,"completion":246,"start":247,"conditions":248,"interventions":250},"NCT00503217","GnRH Agonist and Intrauterine Insemination",[44],"2007-12","2005-02",[249],"Intrauterine Insemination",[230],{"trials":252,"activeCount":52},[],{"intervention":254,"totalTrials":48,"cells":255},"Agonist GnRH; estradiol Valerate; progesterone",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":276},{"trials":257,"activeCount":52},[],{"trials":259,"activeCount":52},[],{"trials":261,"activeCount":52},[],{"trials":263,"activeCount":52},[],{"trials":265,"activeCount":52},[266],{"nctId":267,"briefTitle":268,"status":269,"phases":270,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":275},"NCT01353846","Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients","UNKNOWN",[44],"2012-11","2011-05",70,[15],[254],{"trials":277,"activeCount":52},[],{"intervention":279,"totalTrials":48,"cells":280},"r-FSH",{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":289,"NA":301},{"trials":282,"activeCount":52},[],{"trials":284,"activeCount":52},[],{"trials":286,"activeCount":52},[],{"trials":288,"activeCount":52},[],{"trials":290,"activeCount":52},[291],{"nctId":292,"briefTitle":293,"status":105,"phases":294,"completion":295,"start":296,"conditions":297,"interventions":298},"NCT00829075","Impact of Three Different Gonadotrophin Regimes on Egg Donation Program",[44],"2006-12","2005-01",[28],[279,299,300],"HP-hMG","r-FSH plus HP-hMG",{"trials":302,"activeCount":52},[],{"intervention":299,"totalTrials":48,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":319},{"trials":306,"activeCount":52},[],{"trials":308,"activeCount":52},[],{"trials":310,"activeCount":52},[],{"trials":312,"activeCount":52},[],{"trials":314,"activeCount":52},[315],{"nctId":292,"briefTitle":293,"status":105,"phases":316,"completion":295,"start":296,"conditions":317,"interventions":318},[44],[28],[279,299,300],{"trials":320,"activeCount":52},[],{"intervention":300,"totalTrials":48,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":337},{"trials":324,"activeCount":52},[],{"trials":326,"activeCount":52},[],{"trials":328,"activeCount":52},[],{"trials":330,"activeCount":52},[],{"trials":332,"activeCount":52},[333],{"nctId":292,"briefTitle":293,"status":105,"phases":334,"completion":295,"start":296,"conditions":335,"interventions":336},[44],[28],[279,299,300],{"trials":338,"activeCount":52},[],{"intervention":340,"totalTrials":48,"cells":341},"Cetrorelix and Leuprolide",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":359},{"trials":343,"activeCount":52},[],{"trials":345,"activeCount":52},[],{"trials":347,"activeCount":52},[],{"trials":349,"activeCount":52},[],{"trials":351,"activeCount":52},[352],{"nctId":353,"briefTitle":354,"status":105,"phases":355,"conditions":356,"interventions":358},"NCT00505817","GnRH Agonist and Antagonists in an Oocyte Donation Program",[44],[357],"Effect of Two Protocols of Ovarian Stimulation on Oocyte Quality",[340],{"trials":360,"activeCount":52},[],{"intervention":362,"totalTrials":48,"cells":363},"Antagonist GnRH Cetrotide",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":384},{"trials":365,"activeCount":52},[],{"trials":367,"activeCount":52},[],{"trials":369,"activeCount":52},[],{"trials":371,"activeCount":52},[],{"trials":373,"activeCount":52},[374],{"nctId":375,"briefTitle":376,"status":105,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":382},"NCT00633347","Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation",[44],"2009-10","2007-01",570,[15],[362,383],"Agonist GnRH Acetate Triptoreline",{"trials":385,"activeCount":52},[],{"intervention":383,"totalTrials":48,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":402},{"trials":389,"activeCount":52},[],{"trials":391,"activeCount":52},[],{"trials":393,"activeCount":52},[],{"trials":395,"activeCount":52},[],{"trials":397,"activeCount":52},[398],{"nctId":375,"briefTitle":376,"status":105,"phases":399,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":400,"interventions":401},[44],[15],[362,383],{"trials":403,"activeCount":52},[],{"intervention":405,"totalTrials":48,"cells":406},"GnRH antagonist",{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":426,"NA":428},{"trials":408,"activeCount":52},[],{"trials":410,"activeCount":52},[],{"trials":412,"activeCount":52},[],{"trials":414,"activeCount":52},[415],{"nctId":416,"briefTitle":417,"status":105,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":425},"NCT01268761","GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome",[43],"2013-07","2012-04",100,[24,423,424],"Effects of Gonadotropin","Oocyte Maturation",[405],{"trials":427,"activeCount":52},[],{"trials":429,"activeCount":52},[],{"intervention":431,"totalTrials":48,"cells":432},"Provera 10 mg.",{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":450,"NA":452},{"trials":434,"activeCount":52},[],{"trials":436,"activeCount":52},[],{"trials":438,"activeCount":52},[],{"trials":440,"activeCount":52},[441],{"nctId":442,"briefTitle":443,"status":105,"phases":444,"primaryCompletion":445,"completion":445,"start":446,"enrollment":67,"conditions":447,"interventions":448},"NCT03300960","Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation",[43],"2019-06-25","2017-10-20",[15],[431,449],"Ganirelix",{"trials":451,"activeCount":52},[],{"trials":453,"activeCount":52},[],{"intervention":449,"totalTrials":48,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":468,"NA":470},{"trials":457,"activeCount":52},[],{"trials":459,"activeCount":52},[],{"trials":461,"activeCount":52},[],{"trials":463,"activeCount":52},[464],{"nctId":442,"briefTitle":443,"status":105,"phases":465,"primaryCompletion":445,"completion":445,"start":446,"enrollment":67,"conditions":466,"interventions":467},[43],[15],[431,449],{"trials":469,"activeCount":52},[],{"trials":471,"activeCount":52},[],{"intervention":473,"totalTrials":48,"cells":474},"Human Menopausal Gonadotropin",{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":489,"NA":491},{"trials":476,"activeCount":52},[],{"trials":478,"activeCount":52},[],{"trials":480,"activeCount":52},[],{"trials":482,"activeCount":52},[483],{"nctId":484,"briefTitle":485,"status":105,"phases":486,"conditions":487,"interventions":488},"NCT00669786","Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles",[43],[28],[473],{"trials":490,"activeCount":52},[],{"trials":492,"activeCount":52},[],{"intervention":494,"totalTrials":48,"cells":495},"Ulipristal Acetate",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":515,"NA":517},{"trials":497,"activeCount":52},[],{"trials":499,"activeCount":52},[],{"trials":501,"activeCount":52},[],{"trials":503,"activeCount":52},[504],{"nctId":505,"briefTitle":506,"status":507,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":11,"conditions":511,"interventions":514},"NCT02425878","Ulipristal Acetate 10 mg and Asisted Reproduction","TERMINATED",[43],"2016-05-31","2015-10-19",[512,513],"Intramural Fibroids","Uterine Fibroids",[494],{"trials":516,"activeCount":52},[],{"trials":518,"activeCount":52},[],{"intervention":520,"totalTrials":48,"cells":521},"Cabergoline",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":539,"NA":541},{"trials":523,"activeCount":52},[],{"trials":525,"activeCount":52},[],{"trials":527,"activeCount":52},[],{"trials":529,"activeCount":52},[530],{"nctId":531,"briefTitle":532,"status":105,"phases":533,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":538},"NCT00440258","Cabergoline Reduces OHSS",[43],"2006-07","2004-04",60,[24],[520],{"trials":540,"activeCount":52},[],{"trials":542,"activeCount":52},[],{"intervention":544,"totalTrials":48,"cells":545},"FSH+LH",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":563,"NA":565},{"trials":547,"activeCount":52},[],{"trials":549,"activeCount":52},[],{"trials":551,"activeCount":52},[],{"trials":553,"activeCount":52},[554],{"nctId":555,"briefTitle":556,"status":105,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":562},"NCT01563809","Basal Androgens and LH Needing for Ovarian Stimulation for in Vitro Fertilization",[43],"2010-12","2008-12",400,[15],[544,544],{"trials":564,"activeCount":52},[],{"trials":566,"activeCount":52},[],{"intervention":568,"totalTrials":48,"cells":569},"rFSH: Follicle Stimulating Hormone",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":587,"NA":589},{"trials":571,"activeCount":52},[],{"trials":573,"activeCount":52},[],{"trials":575,"activeCount":52},[],{"trials":577,"activeCount":52},[578],{"nctId":579,"briefTitle":580,"status":105,"phases":581,"primaryCompletion":582,"completion":582,"start":296,"enrollment":583,"conditions":584,"interventions":585},"NCT01037699","Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles",[43],"2008-03",720,[28],[568,568,586,586],"rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone",{"trials":588,"activeCount":52},[],{"trials":590,"activeCount":52},[],{"intervention":586,"totalTrials":48,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":605,"NA":607},{"trials":594,"activeCount":52},[],{"trials":596,"activeCount":52},[],{"trials":598,"activeCount":52},[],{"trials":600,"activeCount":52},[601],{"nctId":579,"briefTitle":580,"status":105,"phases":602,"primaryCompletion":582,"completion":582,"start":296,"enrollment":583,"conditions":603,"interventions":604},[43],[28],[568,568,586,586],{"trials":606,"activeCount":52},[],{"trials":608,"activeCount":52},[],{"intervention":610,"totalTrials":48,"cells":611},"200 mg of Progesterone",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":631,"NA":633},{"trials":613,"activeCount":52},[],{"trials":615,"activeCount":52},[],{"trials":617,"activeCount":52},[],{"trials":619,"activeCount":52},[620],{"nctId":621,"briefTitle":622,"status":105,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":629},"NCT00480402","Natural Progesterone and Preterm Birth in Twins",[43],"2007-06","2006-01",290,[628],"Preterm Birth",[610,630],"400 mg Progesterone",{"trials":632,"activeCount":52},[],{"trials":634,"activeCount":52},[],{"intervention":630,"totalTrials":48,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":649,"NA":651},{"trials":638,"activeCount":52},[],{"trials":640,"activeCount":52},[],{"trials":642,"activeCount":52},[],{"trials":644,"activeCount":52},[645],{"nctId":621,"briefTitle":622,"status":105,"phases":646,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":647,"interventions":648},[43],[628],[610,630],{"trials":650,"activeCount":52},[],{"trials":652,"activeCount":52},[],{"intervention":654,"totalTrials":48,"cells":655},"Quinagolide",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":672,"PHASE4":674,"NA":676},{"trials":657,"activeCount":52},[],{"trials":659,"activeCount":52},[],{"trials":661,"activeCount":52},[662],{"nctId":663,"briefTitle":664,"status":105,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":671},"NCT00665041","Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome",[42],"2008-08","2008-10","2008-05",30,[24],[654],{"trials":673,"activeCount":52},[],{"trials":675,"activeCount":52},[],{"trials":677,"activeCount":52},[],{"intervention":679,"totalTrials":48,"cells":680},"Gonadotrophins",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":689,"NA":691},{"trials":682,"activeCount":52},[],{"trials":684,"activeCount":52},[],{"trials":686,"activeCount":52},[],{"trials":688,"activeCount":52},[],{"trials":690,"activeCount":52},[],{"trials":692,"activeCount":52},[693],{"nctId":694,"briefTitle":695,"status":105,"phases":696,"primaryCompletion":697,"completion":697,"start":559,"enrollment":669,"conditions":698,"interventions":700},"NCT00802295","Aneuploidies and Different Stimulation Protocols",[45],"2009-04",[699],"Aneuploidy",[679,701],"Low dosis Gonadotrophin",{"intervention":701,"totalTrials":48,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":705,"activeCount":52},[],{"trials":707,"activeCount":52},[],{"trials":709,"activeCount":52},[],{"trials":711,"activeCount":52},[],{"trials":713,"activeCount":52},[],{"trials":715,"activeCount":52},[716],{"nctId":694,"briefTitle":695,"status":105,"phases":717,"primaryCompletion":697,"completion":697,"start":559,"enrollment":669,"conditions":718,"interventions":719},[45],[699],[679,701],{"intervention":721,"totalTrials":48,"cells":722},"Ionomycin SIGMA",{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":724,"activeCount":52},[],{"trials":726,"activeCount":52},[],{"trials":728,"activeCount":52},[],{"trials":730,"activeCount":52},[],{"trials":732,"activeCount":52},[],{"trials":734,"activeCount":52},[735],{"nctId":736,"briefTitle":737,"status":269,"phases":738,"primaryCompletion":739,"completion":739,"start":740,"enrollment":741,"conditions":742,"interventions":743},"NCT06106412","Efficacy of Oocyte Activation With Two Types of Ca2+ Ionophore.",[45],"2024-12","2024-01-01",44,[18],[721,744],"A23187",{"intervention":744,"totalTrials":48,"cells":746},{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":755,"NA":757},{"trials":748,"activeCount":52},[],{"trials":750,"activeCount":52},[],{"trials":752,"activeCount":52},[],{"trials":754,"activeCount":52},[],{"trials":756,"activeCount":52},[],{"trials":758,"activeCount":52},[759],{"nctId":736,"briefTitle":737,"status":269,"phases":760,"primaryCompletion":739,"completion":739,"start":740,"enrollment":741,"conditions":761,"interventions":762},[45],[18],[721,744],{"intervention":764,"totalTrials":48,"cells":765},"Controlled ovarian stimuation",{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":774,"NA":776},{"trials":767,"activeCount":52},[],{"trials":769,"activeCount":52},[],{"trials":771,"activeCount":52},[],{"trials":773,"activeCount":52},[],{"trials":775,"activeCount":52},[],{"trials":777,"activeCount":52},[778],{"nctId":779,"briefTitle":780,"status":269,"phases":781,"primaryCompletion":782,"completion":782,"start":783,"enrollment":19,"conditions":784,"interventions":785},"NCT06103383","Second Phase of the Pilot Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women",[45],"2024-12-31","2023-02-28",[18,424],[764]]